Board to approve September 2026 quarterly and half-year results

Results View source PDF Explain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.1%Reaction day

₹1809.20

prior close

₹1856.00

announcement price

In-mkt

timing

Nifty Smallcap 250market+2.2%+1.9% vs market

Pharmaceuticals peers, median of 173sector+2.0%+2.1% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Smallcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.3

15m

+0.4

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.1+2.2+1.9+2.0+2.1

Next day

+5.5pendingpending+2.6+2.8

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wockhardt's board will meet on 2 November 2026 to approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. Trading in the company's shares remains closed until 48 hours after the results are declared.

Likely market impact

No financial figures were disclosed. Investors should await the results, as trading remains closed until 48 hours after the declaration.